Lexeo Therapeutics, Inc. Stock-Based Compensation
Lexeo Therapeutics, Inc. (LXEO) reported Stock-Based Compensation of $8.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.69M, a 85.28% increase year-over-year.
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.75M, a 25.48% decline year-over-year.
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.71M, a 22.64% decline year-over-year.
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.65M, a 30.05% decline year-over-year.
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $12.13M, a 2.74% decline from fiscal 2024.
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $12.47M, a 309.92% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $3.04M, a 70.86% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.78M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $8.45M 10-Q · filed 2026-08-12 | $11.16M derived: sum of 3 quarters · filed 2026-08-12 | $13.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.75M 10-Q · filed 2026-05-11 | $5.47M derived: sum of 2 quarters · filed 2026-05-11 | $8.12M derived: sum of 3 quarters · filed 2026-05-11 | $11.19M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.36M derived: sum of 2 quarters · filed 2026-03-30 | $8.44M derived: sum of 3 quarters · filed 2026-08-12 | $12.13M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.72M derived: sum of 2 quarters · filed 2026-08-12 | $9.42M 10-Q · filed 2025-11-05 | $12.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.77M 10-Q · filed 2026-08-12 | $10.28M derived: sum of 3 quarters · filed 2026-08-12 | $14.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.70M 10-Q · filed 2026-05-11 | $7.20M derived: sum of 2 quarters · filed 2026-05-11 | $10.99M derived: sum of 3 quarters · filed 2026-05-11 | $13.84M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.30M derived: sum of 2 quarters · filed 2026-03-30 | $10.14M derived: sum of 3 quarters · filed 2026-03-30 | $12.47M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.64M derived: sum of 2 quarters · filed 2025-11-05 | $8.97M 10-Q · filed 2025-11-05 | $9.77M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.18M 10-Q · filed 2025-08-14 | $5.98M derived: sum of 3 quarters · filed 2025-08-14 | $6.86M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.33M 10-Q · filed 2025-05-12 | $3.13M derived: sum of 2 quarters · filed 2025-05-12 | $4.01M derived: sum of 3 quarters · filed 2025-05-12 | $4.98M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $804.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.68M derived: sum of 2 quarters · filed 2025-03-24 | $2.65M derived: sum of 3 quarters · filed 2025-03-24 | $3.04M 10-K · filed 2025-03-24 |
| 2023-09-30 | $875.00K 10-Q · filed 2023-12-11 | $1.84M derived: sum of 2 quarters · filed 2024-08-12 | $2.24M 10-Q · filed 2024-11-13 | $2.76M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-06-30 | $969.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.37M 10-Q · filed 2024-08-12 | $1.89M derived: sum of 3 quarters · filed 2024-08-12 | $2.32M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $397.00K 10-Q · filed 2024-05-09 | $918.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.35M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $521.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $952.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.78M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $431.00K 10-Q · filed 2023-12-11 | $1.26M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |